German RWE on High-Risk AML – Clinical Short Video
Watch this short promotional video from Jazz Pharmaceuticals on a summary of the German Real World Evidence (RWE) on high-risk* AML published by Rautenberg et al (2021)
Prescribing information and adverse event reporting details is available in the video
*High-risk AML defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC)
French RWE on High-Risk AML – Clinical Short Video
Watch this short promotional video from Jazz Pharmaceuticals on a summary of the French Real World Evidence (RWE) on high-risk* AML published by Chiche et al (2021)
Prescribing information and adverse event reporting details is available in the video
*High-risk AML defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC)
Italian RWE on High-Risk AML – Clinical Short Video
Watch this short promotional video from Jazz Pharmaceuticals on a summary of the Italian Real World Evidence (RWE) on high-risk* AML published by Guolo et al (2021)
Prescribing information and adverse event reporting details is available in the video
*High-risk AML defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC)
5-Year Follow-up Data in High-Risk AML – Clinical Short Video
Watch this short promotional video from Jazz Pharmaceuticals on a summary of the 5-year follow-up data in high-risk* AML published by Lancet et al (2021)
Prescribing information and adverse event reporting details is available in the video
*High-risk AML defined as newly diagnosed, therapy-related AML (t-AML) or AML with myelodysplasia related changes (AML-MRC)
Job code: INT-VYX-2100193
Date of prep: January 2022
